Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556108 | 0.82 | NOS1 (0.55) | AADATGFERTMEM97SIGMAR1NPSR1 | |
| SCHEMBL4640604 | 0.81 | AADAT (0.45) | AADATGFERTMEM97SIGMAR1NPSR1 | |
| SCHEMBL6468480 | 0.79 | AADAT (0.57) | AADATGFERTMEM97SIGMAR1PREP | |
| SCHEMBL28716810 | 0.79 | TMEM97 (0.50) | AADATGFERTMEM97SIGMAR1NPSR1 | |
| SCHEMBL29174258 | 0.77 | HSD11B1 (0.54) | AADATTMEM97SIGMAR1PREPACE2 | |
| SCHEMBL953138 | 0.77 | AADAT (0.52) | AADATGFERTMEM97SIGMAR1PREP | |
| SCHEMBL955550 | 0.77 | AADAT (0.50) | AADATGFERTMEM97SIGMAR1NPSR1 | |
| SCHEMBL955548 | 0.77 | AADAT (0.50) | AADATGFERTMEM97SIGMAR1NPSR1 | |
| SCHEMBL3561030 | 0.77 | AADAT (0.57) | AADATTMEM97SIGMAR1PREPACE2 | |
| SCHEMBL953139 | 0.77 | AADAT (0.52) | AADATGFERTMEM97SIGMAR1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | COUSINS RUSSELL D | 2008-11-27 | — | — | US | disclosed |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | COUSINS RUSSELL D | 2008-11-27 | — | — | US | disclosed |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | COUSINS RUSSELL D | 2008-11-27 | — | — | US | disclosed |
| EP-1954694-A1 | IMIDAZOLE DERIVATIVES AS NITRIC OXIDE SYNTHASE DIMERISATION INHIBITOR | Kalypsys, Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070197609-A1 | SALTS OF INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| EP-1817030-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | Kalypsys, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007062410-A1 | IMIDAZOLE DERIVATIVES AS NITRIC OXIDE SYNTHASE DIMERISATION INHIBITOR | KALYPSYS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062417-A1 | METHODS OF PREPARING 2-IMIDAZOL-1-YL-4-METHYL-6-PYRROLIDIN-2-YL-PYRIMIDINE AND 4-(1-ALKYLPYRROLIDIN-2-YL)-2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDINE DERIVATIVES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062417-A1 | METHODS OF PREPARING 2-IMIDAZOL-1-YL-4-METHYL-6-PYRROLIDIN-2-YL-PYRIMIDINE AND 4-(1-ALKYLPYRROLIDIN-2-YL)-2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDINE DERIVATIVES | KALYPSYS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006060424-A2 | INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | KALYPSYS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | AADAT 3829/4885GFER 123/4885TMEM97 3514/4885 |
| US-20070197609-A1 | SALTS OF INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS | NOS2, NOS1, NOS3 | AADAT 1584/4885GFER 171/4885TMEM97 2146/4885 |
| US-20080293942-A1 | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives | NOS2, NOS1, NOS3 | AADAT 1712/4885GFER 1713/4885TMEM97 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.